GW will be paying for the development of other therapies besides Sativex. For Sativex in cancer pain and MS spasticity they have partners, but for glioma, epilepsy, etc they are going it alone. Epidolex for epilepsy figures prominently in the prospectus. You can read it at the SEC Edgar site. I felt MUCH better after reading "use of proceeds". Yet another signal. I'll bet the additional shares will be offered at a much higher price than the current price - wink wink.